Late-breaking dupixent® (dupilumab) data at ers 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Results from the longest global phase 3 open-label extension trial in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years tarrytown, n.y. and paris , sept.
REGN Ratings Summary
REGN Quant Ranking